Molecular recognition of the NPY hormone family by their receptors

Nutrition

Volumn 24, Issue 9, 2008, Pages 907-917

  Lindner, Diana ^a   Stichel, Jan ^a   Beck Sickinger, Annette G ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Ligands; Neuropeptide Y; Y receptor

Indexed keywords

ARGININE; ASPARTIC ACID; LIGAND; NEUROPEPTIDE Y; NEUROPEPTIDE Y1 RECEPTOR; NEUROPEPTIDE Y2 RECEPTOR; NEUROPEPTIDE Y4 RECEPTOR; NEUROPEPTIDE Y5 RECEPTOR; PANCREAS POLYPEPTIDE; PEPTIDE YY;

CHIMERA; CONTROLLED STUDY; HUMAN; LIGAND BINDING; MOLECULAR RECOGNITION; MUTAGENESIS; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW;

AMINO ACID SEQUENCE; ANIMALS; HUMANS; LIGANDS; MICE; MOLECULAR SEQUENCE DATA; MUTAGENESIS; NEUROPEPTIDE Y; PANCREATIC POLYPEPTIDE; PEPTIDE YY; PROTEIN BINDING; RATS; RECEPTORS, NEUROPEPTIDE;

EID: 49949111829     PISSN: 08999007     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nut.2008.06.025     Document Type: Review

References (41)

1. Tatemoto K. Neuropeptide Y. complete amino acid sequence of the brain peptide. Proc Natl Acad Sci U S A 79 (1982) 5485-5489
2. Kalra S.P., and Kalra P.S. NPY and cohorts in regulating appetite, obesity and metabolic syndrome: beneficial effects of gene therapy. Neuropeptides 38 (2004) 201-211
3. Tatemoto K. Isolation and characterization of peptide YY (PYY), a candidate gut hormone that inhibits pancreatic exocrine secretion. Proc Natl Acad Sci U S A 79 (1982) 2514-2518
4. Ekblad E., and Sundler F. Distribution of pancreatic polypeptide and peptide YY. Peptides 23 (2002) 251-261
5. Kimmel J.R., Hayden L.J., and Pollock H.G. Isolation and characterization of a new pancreatic polypeptide hormone. J Biol Chem 250 (1975) 9369-9376
6. Hazelwood R.L. The pancreatic polypeptide (PP-fold) family: gastrointestinal, vascular, and feeding behavioral implications. Proc Soc Exp Biol Med 202 (1993) 44-63
7. Blundell T.L., Pitts J.E., Tickle I.J., Wood S.P., and Wu C.W. X-ray analysis (1. 4-A resolution) of avian pancreatic polypeptide: Small globular protein hormone. Proc Natl Acad Sci U S A 78 (1981) 4175-4179
8. Merten N., and Beck-Sickinger A.G. Molecular ligand-receptor interaction of the NPY/PP peptide family. In: Zukowska Z., and Feuerstein G.Z. (Eds). NPY Family of Peptides in Neurobiology, cardiovascular and Metabolic Disorders: from Genes to Therapeutics. Vol. 95 (2006), Birkhäuser, Basel, Boston, Berlin 35-62
9. Cherezov V., Rosenbaum D.M., Hanson M.A., Rasmussen S.G., Thian F.S., Kobilka T.S., et al. High-resolution crystal structure of an engineered human β2-adrenergic G protein coupled receptor. Science (2007)
10. Palczewski K., Kumasaka T., Hori T., Behnke C.A., Motoshima H., Fox B.A., et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289 (2000) 739-745
11. Holliday N.D., and Cox H.M. Control of signalling efficacy by palmitoylation of the rat Y1 receptor. Br J Pharmacol 139 (2003) 501-512
12. Beck-Sickinger A.G., Wieland H.A., Wittneben H., Willim K.D., Rudolf K., and Jung G. Complete L-alanine scan of neuropeptide Y reveals ligands binding to Y1 and Y2 receptors with distinguished conformations. Eur J Biochem 225 (1994) 947-958
13. Merten N., Lindner D., Rabe N., Rompler H., Morl K., Schoneberg T., and Beck-Sickinger A.G. Receptor subtype-specific docking of Asp6.59 with C-terminal arginine residues in Y receptor ligands. J Biol Chem 282 (2007) 7543-7551
14. Li J.H., Choe H., Wang A.F., Maiti K., Wang C., Salam A., et al. Extracellular loop 3 (EL3) and EL3-proximal transmembrane helix 7 of the mammalian type I and type II gonadotropin-releasing hormone (GnRH) receptors determine differential ligand selectivity to GnRH-I and GnRH-II. Mol Pharmacol 67 (2005) 1099-1110
15. Cho H.J., Moon M.J., Kwon H.B., Hwang J.I., and Seong J.Y. Extracellular loop 3 (ECL3) and ECL3-proximal transmembrane domains VI and VII of the mesotocin and vasotocin receptors confer differential ligand selectivity and signaling activity. Gen Comp Endocrinol 156 (2008) 71-82
16. Robin-Jagerschmidt C., Sylte I., Bihoreau C., Hendricksen L., Calvet A., Dahl S.G., and Benicourt C. The ligand binding site of NPY at the rat Y1 receptor investigated by site-directed mutagenesis and molecular modeling. Mol Cell Endocrinol 139 (1998) 187-198
17. Rudolf K., Eberlein W., Engel W., Wieland H.A., Willim K.D., Entzeroth M., et al. The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226. Eur J Pharmacol 271 (1994) R11-R13
18. Cabrele C., and Beck-Sickinger A.G. Molecular characterization of the ligand-receptor interaction of the neuropeptide Y family. J Pept Sci 6 (2000) 97-122
19. Bitran M., Daniels A.J., and Boric M.P. GW1229, a novel neuropeptide Y Y1 receptor antagonist, inhibits the vasoconstrictor effect on neuropeptide Y in the hamster microcirculation. Eur J Pharmacol 319 (1997) 43-47
20. Balasubramaniam A., Dhawan V.C., Mullins D.E., Chance W.T., Sheriff S., Guzzi M., et al. Highly selective and potent neuropeptide Y (NPY) Y1 receptor antagonists based on [Pro(30), Tyr(32), Leu(34)]NPY(28-36)-NH2 (BW1911U90). J Med Chem 44 (2001) 1479-1482
21. Koglin N., Zorn C., Beumer R., Cabrele C., Bubert C., Sewald N., et al. Analogues of neuropeptide Y containing beta-aminocyclopropane carboxylic acids are the shortest linear peptides that are selective for the Y1 receptor. Angew Chem Int Ed Engl 42 (2003) 202-205
22. Walker P., Munoz M., Martinez R., and Peitsch M.C. Acidic residues in extracellular loops of the human Y1 neuropeptide Y receptor are essential for ligand binding. J Biol Chem 269 (1994) 2863-2869
23. Munch G., Walker P., Shine J., and Herzog H. Ligand binding analysis of human neuropeptide Y1 receptor mutants expressed in E. coli. Receptors Channels 3 (1995) 291-297
24. Sautel M., Rudolf K., Wittneben H., Herzog H., Martinez R., Munoz M., et al. Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor. Mol Pharmacol 50 (1996) 285-292
25. Sjodin P., Holmberg S.K., Akerberg H., Berglund M.M., Mohell N., and Larhammar D. Re-evaluation of receptor-ligand interactions of the human neuropeptide Y receptor Y1: a site-directed mutagenesis study. Biochem J 393 (2006) 161-169
26. Sautel M., Martinez R., Munoz M., Peitsch M.C., Beck-Sickinger A.G., and Walker P. Role of a hydrophobic pocket of the human Y1 neuropeptide Y receptor in ligand binding. Mol Cell Endocrinol 112 (1995) 215-222
27. Kannoa T., Kanatani A., Keen S.L., Arai-Otsuki S., Haga Y., Iwama T., et al. Different binding sites for the neuropeptide Y Y1 antagonists 1229U91 and J-104870 on human Y1 receptors. Peptides 22 (2001) 405-413
28. Du P., Salon J.A., Tamm J.A., Hou C., Cui W., Walker M.W., et al. Modeling the G-protein-coupled neuropeptide Y Y1 receptor agonist and antagonist binding sites. Protein Eng 10 (1997) 109-117
29. Doods H., Gaida W., Wieland H.A., Dollinger H., Schnorrenberg G., Esser F., et al. BIIE0246: a selective and high affinity neuropeptide Y Y(2) receptor antagonist. Eur J Pharmacol 384 (1999) R3-R5
30. Berglund M.M., Fredriksson R., Salaneck E., and Larhammar D. Reciprocal mutations of neuropeptide Y receptor Y2 in human and chicken identify amino acids important for antagonist binding. FEBS Lett 518 (2002) 5-9
31. Eckard C.P., Cabrele C., Wieland H.A., and Beck-Sickinger A. Characterisation of neuropeptide Y receptor subtypes by synthetic NPY analogues and by anti-receptor antibodies. Molecules 6 (2001) 448-467
32. Gerald C., Walker M.W., Criscione L., Gustafson E.L., Batzl-Hartmann C., Smith K.E., et al. A receptor subtype involved in neuropeptide-Y-induced food intake. Nature 382 (1996) 168-171
33. Hu Y., Bloomquist B.T., Cornfield L.J., DeCarr L.B., Flores-Riveros J.R., Friedman L., et al. Identification of a novel hypothalamic neuropeptide Y receptor associated with feeding behavior. J Biol Chem 271 (1996) 26315-26319
34. Rodriguez M., Audinot V., Dromaint S., Macia C., Lamamy V., Beauverger P., et al. Molecular identification of the long isoform of the human neuropeptide Y Y5 receptor and pharmacological comparison with the short Y5 receptor isoform. Biochem J 369 (2003) 667-673
35. Cox H.M. Neuropeptide Y receptors; antisecretory control of intestinal epithelial function. Auton Neurosci 133 (2007) 76-85
36. Berglund M.M., Hipskind P.A., and Gehlert D.R. Recent developments in our understanding of the physiological role of PP-fold peptide receptor subtypes. Exp Biol Med (Maywood) 228 (2003) 217-244
37. Cabrele C., Wieland H.A., Koglin N., Stidsen C., and Beck-Sickinger A.G. Ala31-Aib32: identification of the key motif for high affinity and selectivity of neuropeptide Y at the Y5-receptor. Biochemistry 41 (2002) 8043-8049
38. Kanatani A., Ishihara A., Iwaasa H., Nakamura K., Okamoto O., Hidaka M., et al. L-152,804: orally active and selective neuropeptide Y Y5 receptor antagonist. Biochem Biophys Res Commun 272 (2000) 169-173
39. Erondu N., Wadden T., Gantz I., Musser B., Nguyen A.M., Bays H., et al. Effect of NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-induced weight loss. Obesity (Silver Spring) 15 (2007) 895-905
40. Lindner D., van Dieck J., Merten N., Morl K., Gunthe R., Hofmann H.J., and Beck-Sickinger A.G. GPC receptors and not ligands decide the binding mode in neuropeptide Y multireceptor/multiligand system. Biochem 47 (2008) 5905-5914
41. Larhammar D., Wraith A., Berglund M.M., Holmberg S.K., and Lundell I. Origins of the many NPY-family receptors in mammals. Peptides 22 (2001) 295-307